Investor and corporate-development teams need decision material that translates scientific claims into clear signals for valuation, risk, and execution. Assignments focus on scientific diligence for platform and asset deals, targeted sweeps of efficacy and safety evidence, translational plausibility reviews, and concise decision notes for investment committees. Materials are written in English and shaped so technical reviewers and finance stakeholders can rely on the same document without loss of scientific precision.
Diligence begins with the thesis, the gating questions, and the portfolio fit. Literature is scanned with protocolled queries, selection rules, and date-stamped runs; quality is profiled with tools appropriate to design (for example, RoB 2 for trials and ROBINS-I for non-randomised studies). Effect direction and magnitude are made explicit, heterogeneity is examined where pooling is justified, and limitations are stated where they affect use or scale-up. Translational plausibility is assessed across mechanism, model relevance, biomarkers, and patient selection, with flags for reproducibility risk and operational complexity. Safety signals are summarised with consistent coding, dose/exposure ranges, and margins that map to likely regulatory questions.
Decision outputs are concise and auditable. The decision note sets out the question, the options, the rationale, and triggers for confirmatory work, with supporting tables and figures. A short risk register highlights scientific, regulatory, manufacturing, and clinical-operations risks with possible mitigations. When helpful, simple effect-direction plots and traffic-light summaries show where claims are robust versus fragile. For devices and diagnostics, narratives align to MDR/IVDR in the EU and to FDA routes (510(k), De Novo, PMA), with performance framing that uses measures relevant to adoption. Public-market sensitivities and disclosure guardrails are noted to avoid selective release.
Operational delivery matches deal cadence. Draft one arrives on the scheduled date with tracked changes and a comment log explaining key decisions, assumptions, and references. One focused revision round is included to close open questions. Handover includes the decision note, the screened citation library (EndNote/Zotero), exportable tables (CSV/XLSX), and archived search strategies suitable for VDR upload. Confidential material is handled under NDA with encrypted transfer, named-user access, and retention limited to the period specified in the statement of work. Where ongoing monitoring is required, update cadence and triggers are defined at contracting.
Assignments are executed in English for organisations across Europe and beyond. Contracting and invoicing can be arranged in CHF, EUR, NOK, or DKK.